IGC PHARMA INC (IGC)

Company Profile

IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The company is headquartered in Potomac, Maryland and currently employs 61 full-time employees. The company went IPO on 2006-04-13. The company develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. The company also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Company Info

IGC PHARMA INC

10224 Falls Road

Potomac MARYLAND 20854

P: 13019830998

CEO: Ram Mukunda

Employees: 61

Website: https://igcpharma.com/